Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2018 Mar;30(2):107-112.
doi: 10.1097/CCO.0000000000000427.

Cutaneous angiosarcoma: update on biology and latest treatment

Yoshihiro Ishida  1 , Atsushi Otsuka, Kenji Kabashima
Affiliations
Review

Cutaneous angiosarcoma: update on biology and latest treatment

Yoshihiro Ishida et al. Curr Opin Oncol. 2018 Mar.

Abstract

Purpose of review: The present review aims to provide readers with the latest updates on the biology and clinical management of cutaneous angiosarcoma (cAS).

Recent findings: The genomic alteration of cAS is heterogeneous. Mutations are enriched in the mitosis-activated kinase (MAPK) pathway. Functional analysis has identified molecules that may serve as potential markers and therapeutic targets of angiosarcoma. These molecules include survivin, HSP90, FOXM1, miR-497-5p, KCa3.1, and miR210.This body of knowledge has not yet transferred to clinical practice. The mainstay of treatment for cAS remains surgery followed by postoperative radiotherapy. The efficacy of paclitaxel as an adjuvant chemotherapy is suggested.For patients with advanced cAS, paclitaxel is the treatment of choice. There are also second-line treatment options that are supported by evidence of varying strength. A multikinase inhibitor, pazopanib, has been assessed in several studies, most of which support its efficacy for angiosarcoma. Bevacizumab monotherapy may be effective for angiosarcoma. The efficacy of eribulin mesylate and trabectedin for angiosarcoma is currently being assessed. Recent publications highlighted the role of the immune system in the biology of cAS.

Summary: Future research efforts should focus on the following aspects of cAS: drug development directed at recent molecular targets, clinical trials designed specifically for patients with cAS, and the role of immunotherapy for cAS.

PubMed Disclaimer

Figures

Box 1
Box 1
no caption available
See this image and copyright information in PMC

References

    1. Mark RJ, Poen JC, Tran LM, et al. Angiosarcoma: a report of 67 patients and a review of the literature. Cancer 1996; 77:2400–2406. - PubMed
    1. Schöffski P, Chawla S, Maki RG, et al. Eribulin versus dacarbazine in previously treated patients with advanced liposarcoma or leiomyosarcoma: a randomised, open-label, multicentre, phase 3 trial. Lancet 2016; 387:1629–1637. - PubMed
    1. Parvez E, Popovic S, Elavathil L, et al. Early occurrence of angiosarcoma in a woman with a BRCA2 gene variation of unknown significance treated with breast-conserving therapy for bilateral ductal carcinoma: a case report. Clin Breast Cancer 2015; 15:536–538. - PubMed
    1. Sasajima J, Uehara J, Goto T, et al. Pancreatic metastasis of angiosarcoma (Stewart-Treves syndrome) diagnosed using endoscopic ultrasound-guided fine needle aspiration: a case report. Medicine (Baltimore) 2016; 95:e4316. - PMC - PubMed
    1. Behjati S, Tarpey PS, Sheldon H, et al. Recurrent PTPRB and PLCG1 mutations in angiosarcoma. Nat Genet 2014; 46:376–379. - PMC - PubMed

MeSH terms